Docket No. FDA-2018-D-1893-0002, “Patient-Focused Drug Development: Collecting Comprehensive and Representative Input”

As part of its advocacy program in the United States, ACRO submits regulatory comments to US regulators. This comment letter, submitted by ACRO to FDA in 2018 about Docket No. FDA-2018-D-1893-0002, “Patient-Focused Drug Development: Collecting Comprehensive and Representative Input” can be found below.

Docket No. FDA-2018-D-1893-0002, “Patient-Focused Drug Development: Collecting Comprehensive and Representative Input”

Scroll to Top